ClinicalTrials.gov
ClinicalTrials.gov Menu

Search for Biomarkers in Human Glaucoma: Lymphocytes Alterations and Rate of Progression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00981422
Recruitment Status : Completed
First Posted : September 22, 2009
Last Update Posted : September 22, 2009
Sponsor:
Information provided by:
University of Parma

Brief Summary:
The aim of this study was to evaluate the lymphocyte phenotype in primary open- angle glaucoma (POAG) patients compared to healthy subjects of the same age, in order to confirm the importance of immune responses in glaucoma and the possible correlation to the severity of the disease.

Condition or disease
Glaucoma, Open-Angle

Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Search for Biomarkers in Human Glaucoma: Possible Correlations Between Alterations in Peripheral Lymphocytes and Disease Severity
Study Start Date : June 2007
Actual Primary Completion Date : December 2007
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Group/Cohort
Glaucoma patients
POAG patients selected by an ophthalmologist from the Glaucoma Service, Ophthalmology Institute, University of Parma
Healthy
healthy subjects with negative history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection, (e) diabetes, and (f) systemic inflammation



Primary Outcome Measures :
  1. compare the lymphocyte phenotype of POAG patients to healthy subjects of the same age [ Time Frame: the same day of bloodwithdrawal ]

Secondary Outcome Measures :
  1. correlate the immunophenotype of POAG patients to the severity of disease [ Time Frame: within 3 months after blood withdrawal ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic in Parma (University hospital of Parma)
Criteria

Inclusion Criteria:

  • Clinical diagnosis of primary open-angle glaucoma
  • age between 19 an 85 years old

Exclusion Criteria:

  • age less than 19 or more than 85 yrs
  • positive history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection and (e) diabetes, (f)systemic inflammation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00981422


Locations
Italy
Azienda ospedaliera universitaria
Parma, Italy, 43100
Sponsors and Collaborators
University of Parma
Investigators
Principal Investigator: Stefano A Gandolfi, MD Ophthalmology Institute, University of Parma, Italy

Responsible Party: STEFANO GANDOLFI, Professor of Ophthalmology and Chairman, UNIVERSITY OF PARMA
ClinicalTrials.gov Identifier: NCT00981422     History of Changes
Other Study ID Numbers: PARMABIOMARKERS001
First Posted: September 22, 2009    Key Record Dates
Last Update Posted: September 22, 2009
Last Verified: September 2009

Keywords provided by University of Parma:
glaucoma
immunology
immunophenotype

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases